These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25659577)

  • 21. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
    Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
    Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
    Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
    Weber H; Müller D; Müller M; Ortiz A; Birkle M; Umber S; Ketterer C; Siedentopf O; Feger D; Totzke F; Kubbutat M; Schaechtele C; Ballmer-Hofer K; Ehlert JE; Graeser R
    J Biomol Screen; 2014 Dec; 19(10):1350-61. PubMed ID: 25260782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.
    Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI
    Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.
    Saunders VC; Lafitte M; Adrados I; Quereda V; Feurstein D; Ling Y; Fallahi M; Rosenberg LH; Duckett DR
    Mol Pharmacol; 2015 Dec; 88(6):962-9. PubMed ID: 26452771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells.
    Kim MS; Park MJ; Kim SJ; Lee CH; Yoo H; Shin SH; Song ES; Lee SH
    Int J Oncol; 2005 Sep; 27(3):839-46. PubMed ID: 16077936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
    Zhu Z; Liu Y; Li K; Liu J; Wang H; Sun B; Xiong Z; Jiang H; Zheng J; Hu Z
    Carcinogenesis; 2014 Aug; 35(8):1901-10. PubMed ID: 24876153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
    J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Baro M; Lopez Sambrooks C; Quijano A; Saltzman WM; Contessa J
    Clin Cancer Res; 2019 Jan; 25(2):784-795. PubMed ID: 29967251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
    Greenall SA; McKenzie M; Seminova E; Dolezal O; Pearce L; Bentley J; Kuchibhotla M; Chen SC; McDonald KL; Kornblum HI; Endersby R; Adams TE; Johns TG
    Neuro Oncol; 2019 Aug; 21(8):1016-1027. PubMed ID: 31002307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.
    Cai XM; Tao BB; Wang LY; Liang YL; Jin JW; Yang Y; Hu YL; Zha XL
    Int J Cancer; 2005 Dec; 117(6):905-12. PubMed ID: 15986432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.